Dabigatran, an orally administered direct thrombin inhibitor, has comparable efficacy to warfarin with regard to secondary stroke prevention, according to a new subgroup analysis of the Randomised Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. In addition, dabigatran seems to carry a reduced risk of intracranial hemorrhage compared with warfarin.
展开▼
